This document is an excerpt from the EUR-Lex website
Document 62017CN0527
Case C-527/17: Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN
Case C-527/17: Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN
Case C-527/17: Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN
IO C 402, 27.11.2017, p. 11–12
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
27.11.2017 |
EN |
Official Journal of the European Union |
C 402/11 |
Request for a preliminary ruling from the Bundespatentgericht (Germany) lodged on 5 September 2017 — LN
(Case C-527/17)
(2017/C 402/13)
Language of the case: German
Referring court
Bundespatentgericht
Parties to the main proceedings
Applicant: LN
Defendant: Deutsches Patent- und Markenamt
Question referred
Must Article 2 of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (1) be interpreted as meaning that, for the purposes of that regulation, an authorisation under Directive 93/42/EEC (2) for a combined medical device and medicinal product within the meaning of Article 1(4) of Directive 93/42/EEC is to be treated as a valid marketing authorisation under Directive 2001/83/EC (3), where, as part of the authorisation procedure laid down in Annex I, Section 7.4, first paragraph, to Directive 93/42/EEC, the quality, safety and usefulness of the medicinal product component has been verified by the medicinal products authority of a Member State in accordance with Directive 2001/83/EC?
(2) Council Directive 93/42/EEC of 14 June 1993 concerning medical devices (OJ 1993 L 169, p. 1).
(3) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67).